Small Cell Lung Cancer (SCLC)

📋 Key Information Summary

📋

Small cell lung cancer (SCLC) accounts for approximately 13–15% of all lung cancers in Australia, with strong association to cigarette smoking; incidence is declining in line with reduced smoking prevalence.
SCLC is staged as limited stage (LS) (confined to one hemithorax and regional nodes, manageable within a single radiation field) or extensive stage (ES) (disease beyond these boundaries); TNM staging (8th edition) is increasingly used alongside the traditional two-stage system.
Staging workup requires contrast-enhanced CT chest/abdomen/pelvis, brain MRI (mandatory), PET-CT (if available and will change management), and baseline bloods including LDH, sodium, and liver function tests.
SCLC is characterised by rapid doubling time, early dissemination, and initial high chemosensitivity followed by near-universal relapse; median untreated survival is 2–4 months.
Limited-stage first-line: Concurrent chemoradiation with cisplatin (or carboplatin) + etoposide combined with thoracic radiotherapy (45 Gy BID over 3 weeks preferred); deliver within the first 1–2 chemotherapy cycles.
Extensive-stage first-line: Platinum + etoposide with atezolizumab (Tecentriq®) or durvalumab (Imfinzi®) for 4 cycles, followed by maintenance immunotherapy until progression or unacceptable toxicity.
Prophylactic cranial irradiation (PCI) (25 Gy in 10 fractions) is recommended for patients with any-stage SCLC who achieve a good response, reducing brain metastasis risk by ~50% and improving overall survival.
For extensive-stage patients who decline or are unfit for PCI, surveillance brain MRI every 3 months for 12 months is an acceptable alternative.
Second-line options include lurbinectedin (Zepzelca®), temozolomide, topotecan, CAV (cyclophosphamide/doxorubicin/vincristine), or re-challenge with platinum/etoposide if relapse occurs >6 months after first-line (sensitive relapse).
Paraneoplastic syndromes are common: SIADH (15%), Cushing syndrome (ectopic ACTH), Lambert-Eaton myasthenic syndrome, and hypercalcaemia; screen and manage alongside oncological treatment.
Aboriginal and Torres Strait Islander Australians have higher lung cancer incidence and mortality, later-stage presentation, and lower treatment rates; culturally safe pathways and multidisciplinary input are essential.
All SCLC patients should be discussed at a specialist lung cancer multidisciplinary team (MDT) meeting and referred early to palliative care for symptom management alongside active treatment.

Introduction & Australian Epidemiology

Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma of the lung distinguished by rapid proliferation, early metastatic spread, and initial exquisite chemosensitivity. It represents approximately 13–15% of all primary lung malignancies in Australia and is strongly linked to cigarette smoking, with >95% of cases occurring in current or former smokers. The disease is characterised by a very short doubling time (typically 30–60 days) and propensity for early haematogenous dissemination to the brain, liver, adrenal glands, and bone.

In Australia, lung cancer remains the fifth most commonly diagnosed cancer and the leading cause of cancer-related death. SCLC-specific data from the Australian Institute of Health and Welfare (AIHW) indicate approximately 2,000–2,500 new SCLC diagnoses annually. Five-year overall survival remains poor at approximately 6–8% for all stages combined, though limited-stage disease treated with concurrent chemoradiation achieves 2-year survival rates of 20–40%.

The incidence of SCLC has been gradually declining in Australia, paralleling national reductions in smoking prevalence achieved through public health measures such as plain packaging legislation and tobacco excise increases. However, SCLC in never-smokers remains exceptionally rare (<2–3% of cases). Rural and remote Australians, including Aboriginal and Torres Strait Islander peoples, experience disproportionate lung cancer burden due to higher smoking rates and delayed access to diagnosis and treatment.

⚠️

Rapid progression: SCLC is an oncological emergency. Untreated, median survival is only 2–4 months from diagnosis. Urgent referral to a thoracic oncology MDT is required upon clinical or pathological suspicion.

Staging & Classification

Two-Stage System (Veterans Administration Classification)

The traditional two-stage system remains the most widely used framework for SCLC treatment planning in Australia:

Limited Stage

LS-SCLC

Disease confined to one hemithorax and regional mediastinal/supraclavicular lymph nodes that can be encompassed within a tolerable radiation field. Includes ipsilateral pleural effusion if cytology-negative.

~30–40% of diagnoses

Extensive Stage

ES-SCLC

Disease extending beyond limited-stage boundaries: contralateral lung, distant metastases (brain, liver, adrenals, bone, bone marrow), malignant pleural/pericardial effusion, or contralateral supraclavicular nodes.

~60–70% of diagnoses

TNM Staging (AJCC 8th Edition)

The AJCC TNM 8th edition staging system is increasingly applied to SCLC, allowing more precise prognostication. Limited stage broadly corresponds to TNM stages I–IIIB (T1–4, N0–3, M0), while extensive stage corresponds to stage IV (M1a/b/c) or T4/N3 disease not amenable to a single radiation field. TNM staging is recommended for surgical candidates (rare in SCLC) and clinical trial eligibility.

Staging Workup

Essential

Contrast-enhanced CT chest/abdomen/pelvis

Primary staging modality. Assess primary tumour extent, mediastinal lymphadenopathy, hepatic and adrenal metastases. MBS item 56800 series.

Essential

Brain MRI with gadolinium

Mandatory for all stages. SCLC has 10–15% occult brain metastasis rate at diagnosis; MRI is superior to CT for detection. Perform before or within 1 week of treatment initiation.

Available

PET-CT (FDG)

Recommended when curative-intent treatment is planned (especially limited stage) to detect occult nodal or distant disease. Available at major metropolitan centres. Can upstage 10–15% of clinically limited-stage patients to extensive stage. MBS item 61338 (if eligible criteria met).

Essential

Tissue biopsy / cytology

Histopathological or cytological confirmation required. Core biopsy preferred for adequate tissue (immunohistochemistry: CD56, synaptophysin, chromogranin A, Ki-67 typically >80%). Bronchoscopic EBUS-TBNA for central/peribronchial lesions.

Essential

Baseline bloods

FBC, LFTs, LDH, electrolytes (Na⁺ for SIADH), calcium, renal function (eGFR), coagulation studies. LDH is a prognostic marker (elevated LDH associated with worse outcomes).

Available

Bone marrow biopsy

Consider if unexplained cytopenias suggest marrow involvement (especially if PET unavailable). Less commonly required in the PET-CT era.

🚨

Staging pitfall: Do not start treatment based on CT alone. Brain MRI and complete staging must be completed before initiating therapy, as occult brain metastases and/or contralateral disease may shift management from curative-intent chemoradiation to palliative-intent systemic therapy.

Histological Subtypes

SCLC is classified into:

Pure SCLC: Classic small cells with scant cytoplasm, finely granular "salt-and-pepper" chromasm, nuclear moulding, and very high mitotic rate. Accounts for ~90% of cases.
Combined SCLC: SCLC with a component of NSCLC (adenocarcinoma, squamous cell carcinoma, or large cell carcinoma) comprising ≥10% of the tumour. Treat as SCLC unless the NSCLC component is predominant and actionable mutations are identified.

Treatment Approach

First-Line Chemotherapy Backbone

The platinum/etoposide doublet has been the standard of care for SCLC since the 1980s and remains the chemotherapy backbone for both limited and extensive stage disease. In Australia, either cisplatin or carboplatin may be used; carboplatin is preferred for patients with renal impairment, hearing loss, or when reduced infusion time is desired.

💊

Cisplatin + Etoposide (EP regimen)

Platinol® + Vepesid® · Platinum + topoisomerase II inhibitor

Adult dose Cisplatin 60–80 mg/m² IV Day 1 + Etoposide 100–120 mg/m² IV Days 1–3; every 21 days × 4 cycles

Paediatric dose Not applicable (adult malignancy)

Renal adjustment Cisplatin contraindicated if eGFR <60 mL/min; use carboplatin alternative. Etoposide reduce dose if eGFR <50 mL/min (50% dose if eGFR 15–50).

Hepatic adjustment Etoposide: reduce dose by 50% if bilirubin 26–51 µmol/L; avoid if bilirubin >51 µmol/L

PBS status ✔ PBS General Benefit

💊

Carboplatin + Etoposide (CE regimen)

Paraplatin® + Vepesid® · Platinum + topoisomerase II inhibitor

Adult dose Carboplatin AUC 5–6 IV Day 1 + Etoposide 100 mg/m² IV Days 1–3; every 21 days × 4 cycles

Renal adjustment Carboplatin dosed by Calvert formula (AUC × [GFR + 25]); inherently renal-adjusted. Etoposide as above.

PBS status ✔ PBS General Benefit

Immunotherapy Addition (Extensive Stage)

The addition of immune checkpoint inhibitors (ICIs) targeting PD-L1 to platinum/etoposide has become the standard of care for ES-SCLC following the IMpower133 and CASPIAN trials. Two agents are PBS-listed in Australia for this indication:

💊

Atezolizumab

Tecentriq® · PD-L1 monoclonal antibody

Adult dose 1,200 mg IV every 21 days (with carboplatin/etoposide × 4 cycles, then as monotherapy maintenance until progression or unacceptable toxicity)

Key trial IMpower133: median OS 12.3 vs 10.3 months (HR 0.70)

Renal adjustment No specific adjustment required

PBS status ✔ PBS Authority Required

💊

Durvalumab

Imfinzi® · PD-L1 monoclonal antibody

Adult dose 1,500 mg IV every 21 days (with platinum/etoposide × 4 cycles, then 1,500 mg every 28 days as maintenance until progression)

Key trial CASPIAN: median OS 13.0 vs 10.3 months (HR 0.73)

Renal adjustment No specific adjustment required

PBS status ✔ PBS Authority Required

⚠️

Immunotherapy-related adverse events: Immune-mediated toxicities (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, skin reactions) occur in 10–20% of patients. Grade ≥3 toxicities require permanent discontinuation and high-dose corticosteroids (prednisolone 1–2 mg/kg/day). Educate patients to report new cough, breathlessness, diarrhoea, or rash promptly.

Thoracic Radiotherapy

Thoracic radiotherapy (TRT) is a critical component of limited-stage treatment. The preferred regimen is 45 Gy in 30 fractions delivered twice daily (BID) over 3 weeks (Turrisi regimen), concurrent with cycles 1–2 of EP. Hyperfractionated BID TRT demonstrated superior survival compared with once-daily 45 Gy in the pivotal Intergroup 0096 trial. Where BID scheduling is not feasible, once-daily TRT (60–70 Gy over 6–7 weeks) is an acceptable alternative per current evidence.

Prophylactic Cranial Irradiation (PCI)

SCLC has a high propensity for brain metastases: 50–60% at 2 years without PCI. PCI reduces the incidence of brain metastases by approximately 50% and confers an overall survival benefit of ~5% at 3 years. The standard dose is 25 Gy in 10 fractions. PCI is recommended for:

All limited-stage patients who achieve a complete or near-complete response after chemoradiation
Extensive-stage patients who achieve any response to first-line chemotherapy ± immunotherapy
PCI is typically commenced 3–4 weeks after completion of systemic therapy

ℹ️

Neurocognitive effects of PCI: PCI can cause short-term memory impairment and cognitive decline, particularly in elderly patients (≥65 years). Hippocampal-avoidance PCI techniques are under investigation but not yet standard of care. Patients should be counselled about cognitive side effects; neuropsychological assessment before and after PCI is recommended where available.

Timing of Chemotherapy and Radiotherapy

In limited-stage disease, concurrent chemoradiation should commence within the first 1–2 cycles of chemotherapy. Early concurrent therapy (starting with cycle 1 or 2) is associated with superior outcomes compared with delayed sequential therapy. Ensure adequate performance status (ECOG 0–2), pulmonary function (FEV₁ ≥1.0 L), and renal function before initiating concurrent treatment.

Limited Stage Management

Treatment Algorithm

1

Complete staging

CT CAP, brain MRI (mandatory), PET-CT if available. ECOG performance status. MDT discussion.

2

Concurrent chemoradiation

Cisplatin (or carboplatin) + etoposide every 21 days × 4–6 cycles with concurrent thoracic radiotherapy (45 Gy BID preferred) starting cycle 1–2.

3

Re-staging

CT chest/abdomen/pelvis and brain MRI 3–4 weeks after completing chemoradiation. Assess response (RECIST criteria).

4

PCI (if good response)

25 Gy in 10 fractions, commencing 3–4 weeks post-chemoradiation if CR or good PR achieved. If not suitable for PCI, brain MRI surveillance every 3 months × 12 months.

5

Surveillance

CT chest every 3 months × 2 years, then every 6 months × 3 years. Brain MRI if not received PCI. Clinical review every 3 months.

Concurrent Chemoradiation Regimen

Component	Preferred Regimen	Alternative
Chemotherapy	Cisplatin 60 mg/m² Day 1 + Etoposide 120 mg/m² Days 1–3, q21d × 4 cycles	Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1–3, q21d × 4 cycles
Thoracic RT	45 Gy in 30 fractions BID (1.5 Gy/fraction) over 3 weeks	60–70 Gy in 30–35 fractions once daily over 6–7 weeks
RT timing	Commence with cycle 1 or 2 of chemotherapy (early concurrent)	Must be completed by end of cycle 4 at latest
PCI	25 Gy in 10 fractions (post-treatment, if good response)	Omitted with brain MRI surveillance if patient declines or unfit

Surgical Management (Rare)

Surgery plays a very limited role in SCLC and is considered only for clinical stage I (T1–2, N0, M0) disease after thorough staging including mediastinoscopy or EBUS confirmation of N0 status. Adjuvant platinum-based chemotherapy (± PCI) should follow surgical resection. In practice, fewer than 2–5% of SCLC patients in Australia are surgical candidates.

Surveillance Protocols

Following completion of definitive therapy for limited-stage SCLC:

Years 1–2: CT chest/abdomen/pelvis every 3 months; brain MRI every 3–6 months (if no PCI) or at clinician discretion (if PCI delivered)
Years 3–5: CT chest every 6 months; brain MRI annually or if symptomatic
Beyond 5 years: Annual CT chest; clinical review; smoking cessation support; assess for late treatment effects (cardiac, pulmonary fibrosis, neurocognitive decline)

✅

Long-term survivors: Approximately 10–15% of limited-stage SCLC patients treated with concurrent chemoradiation and PCI achieve long-term disease-free survival (>5 years). These patients require ongoing surveillance for second primary lung cancers and late treatment-related toxicity.

Extensive Stage Management

First-Line Therapy

The current standard of care for ES-SCLC in Australia is platinum/etoposide combined with an anti-PD-L1 antibody (atezolizumab or durvalumab) for 4 cycles, followed by maintenance immunotherapy. This represents the most significant advance in SCLC treatment in three decades, providing a modest but clinically meaningful overall survival improvement of approximately 2–3 months compared with chemotherapy alone.

IMpower133 Trial (Atezolizumab)

Phase III, 403 patients. Carboplatin/etoposide ± atezolizumab × 4 cycles → maintenance atezolizumab. Median OS: 12.3 vs 10.3 months (HR 0.70, p=0.007). 1-year OS: 51.7% vs 38.2%. Benefit seen across subgroups.

CASPIAN Trial (Durvalumab)

Phase III, 537 patients. Platinum/etoposide ± durvalumab × 4 cycles → maintenance durvalumab. Median OS: 13.0 vs 10.3 months (HR 0.73, p=0.0047). Flexible platinum choice (cisplatin or carboplatin).

ℹ️

PBS eligibility note: Atezolizumab and durvalumab for ES-SCLC are available on the PBS under Authority Required listing. Eligible patients must have ES-SCLC confirmed by a specialist, ECOG PS 0–1, and no contraindications to immunotherapy. Applications are made via the PBS authority phone line or online portal.

First-Line Regimen Summary

ES-SCLC, ECOG 0–1

Carboplatin AUC 5 D1 + Etoposide 100 mg/m² D1–3 + Atezolizumab 1,200 mg D1 q21d × 4 → Atezolizumab 1,200 mg q21d maintenance

Until progression

PBS Authority Required

ES-SCLC, ECOG 0–1

Platinum + Etoposide + Durvalumab 1,500 mg D1 q21d × 4 → Durvalumab 1,500 mg q28d maintenance

Until progression

PBS Authority Required

ES-SCLC, ECOG 2 or contraindication to ICI

Carboplatin AUC 5 D1 + Etoposide 100 mg/m² D1–3 q21d × 4–6

4–6 cycles

Chemotherapy alone (PBS listed)

Palliative Radiotherapy

Consolidative thoracic radiotherapy may be considered in ES-SCLC patients who achieve a good response to systemic therapy, based on the CREST trial suggesting potential benefit in selected patients. Palliative radiotherapy is indicated for symptomatic metastases (bone pain, superior vena cava obstruction, brain metastases, spinal cord compression).

Management of CNS Metastases

Brain metastases are present in 10–15% of ES-SCLC at diagnosis and develop in up to 50–60% during the disease course. Management depends on symptoms, number of lesions, and performance status:

Clinical Scenario	Recommended Approach
Asymptomatic, limited brain metastases (1–3)	Stereotactic radiosurgery (SRS) if available, followed by systemic therapy. Consider PCI if no prior PCI.
Symptomatic, multiple brain metastases	Dexamethasone 8–16 mg/day IV/PO + whole brain radiotherapy (WBRT, 30 Gy / 10 fractions). Systemic therapy if performance status allows.
Brain metastases with impending herniation	Emergency neurosurgical referral if accessible lesion. Dexamethasone 10 mg IV stat then 4 mg IV q6h. Palliative WBRT.
Previously received PCI, now relapse in brain	SRS preferred if ≤4 lesions; WBRT if widespread. Re-challenge with PCI generally not recommended.

Second-Line and Relapsed Disease

Nearly all SCLC patients will relapse after first-line therapy. Prognosis in relapsed disease is poor, with median survival of 4–6 months. Treatment choice depends on the relapse-free interval:

Refractory disease (progression during or within 90 days of first-line): Poor prognosis; consider clinical trial, lurbinectedin, temozolomide, or best supportive care.
Sensitive relapse (relapse >90 days after completing first-line): Re-challenge with platinum/etoposide is reasonable, particularly if relapse-free interval >6 months. Response rates 25–40%.

💊

Lurbinectedin

Zepzelca® · Selective inhibitor of oncogenic transcription

Adult dose 3.2 mg/m² IV every 21 days until progression or unacceptable toxicity

Indication Relapsed SCLC (sensitive or refractory) after platinum-based therapy

Key toxicities Myelosuppression (neutropenia G3/4: 41%), hepatotoxicity, fatigue, nausea

Renal adjustment No specific adjustment; use with caution if eGFR <30 mL/min

PBS status ✔ PBS Authority Required

💊

Temozolomide

Temodal® · Alkylating agent

Adult dose 150–200 mg/m² PO Days 1–5, every 28 days

Indication Relapsed SCLC; has CNS penetration (useful for brain metastases)

PBS status ✔ PBS Authority Required

💊

Topotecan

Hycamtin® · Topoisomerase I inhibitor

Adult dose 1.5 mg/m² IV Days 1–5, every 21 days; or 2.3 mg/m² PO Days 1–5, every 21 days

Key toxicities Myelosuppression (dose-limiting), diarrhoea, nausea, fatigue

Renal adjustment Reduce dose to 0.75 mg/m² IV if eGFR 20–39 mL/min

PBS status ✔ PBS Authority Required

💊

CAV regimen

Cyclophosphamide + Doxorubicin + Vincristine

Adult dose Cyclophosphamide 1,000 mg/m² IV D1, Doxorubicin 45 mg/m² IV D1, Vincristine 2 mg IV D1, every 21 days

Indication Second-line option for sensitive relapse; alternative to re-challenge with EP

PBS status ✔ PBS General Benefit

Supportive Care & Symptom Management

Early integration of palliative care improves quality of life and may improve survival in SCLC. Key supportive care considerations include:

Pain management: WHO analgesic ladder; radiotherapy for painful bone metastases; bone-modifying agents (denosumab 120 mg SC q4w or zoledronic acid 4 mg IV q4w) for lytic bone metastases
Superior vena cava (SVC) obstruction: Emergency radiotherapy and/or stenting; dexamethasone 8 mg IV
Spinal cord compression: Dexamethasone 16 mg IV stat + urgent MRI + emergency radiotherapy within 24 hours; neurosurgical consultation if instability or diagnostic uncertainty
Neutropenic sepsis: Assess febrile neutropenia risk; G-CSF (filgrastim/pegfilgrastim) support if ≥20% risk per NCCN criteria or previous episode. Empirical piperacillin/tazobactam 4.5 g IV q6h or cefepime 2 g IV q8h as per local protocols
Thromboprophylaxis: Consider LMWH (enoxaparin 40 mg SC daily) for VTE prophylaxis in hospitalised cancer patients; SCLC carries high VTE risk
Anti-emesis: NK1 antagonist (aprepitant) + 5HT3 antagonist (ondansetron) + dexamethasone for highly emetogenic cisplatin-containing regimens

Paraneoplastic Syndromes

Syndrome	Incidence	Mechanism	Management
SIADH	15%	Ectopic ADH secretion	Fluid restriction (<1 L/day), NaCl tablets, demeclocycline, tolvaptan; chemotherapy typically resolves SIADH
Ectopic ACTH / Cushing syndrome	2–5%	Ectopic ACTH production	Ketoconazole 200 mg TDS or metyrapone for cortisol control; treat underlying SCLC urgently
Lambert-Eaton myasthenic syndrome (LEMS)	3%	Anti-VGCC antibodies	3,4-diaminopyridine (amifampridine); IVIG; treat SCLC; may improve with immunotherapy
Dermatomyositis	<1%	Immune-mediated	Corticosteroids; dermatology/rheumatology input; treat underlying malignancy

Special Populations

🤰

Pregnancy

SCLC in pregnancy is exceptionally rare but carries a very poor prognosis for both mother and fetus.

Cisplatin and etoposide are contraindicated in the first trimester (teratogenic); carboplatin/etoposide may be considered in the second/third trimester with MDT discussion involving maternal-fetal medicine.

Immunotherapy (atezolizumab, durvalumab) is contraindicated in pregnancy — crosses the placenta and may cause fetal immune disruption.

Thoracic radiotherapy and PCI are contraindicated in pregnancy.

Multidisciplinary discussion involving oncology, obstetrics, neonatology, and ethics is essential. Early delivery planning may be required.

Cisplatin/etoposide: Teratogenic — Category D. Avoid in first trimester.

Atezolizumab/Durvalumab: Contraindicated in pregnancy.

👶

Paediatrics

Primary pulmonary SCLC is extraordinarily rare in children and adolescents. Pulmonary neuroendocrine tumours in the paediatric population are typically carcinoid tumours, not SCLC.

Paediatric SCLC cases should be managed at a paediatric oncology centre with adult oncology collaboration.

Treatment regimens are extrapolated from adult data; refer to Children's Oncology Group or ANZCHOG protocols if applicable.

Refer to tertiary paediatric oncology centre.

👴

Elderly (≥70 years)

Over 50% of SCLC patients are ≥70 years at diagnosis in Australia. Age alone is not a contraindication to treatment, but comprehensive geriatric assessment (CGA) is recommended.

Carboplatin is generally preferred over cisplatin in elderly patients due to reduced nephrotoxicity and emetogenicity.

Dose attenuation may be required: consider 75–80% of standard doses for ECOG 2 patients or those with significant comorbidities.

PCI neurocognitive toxicity is more pronounced in elderly patients (≥65 years); careful discussion of risks vs benefits is essential; hippocampal-avoidance techniques should be considered if available.

Immune checkpoint inhibitors have similar efficacy and toxicity in elderly patients as in younger cohorts; no dose adjustment required based on age alone.

Use G-CSF prophylaxis liberally in elderly patients receiving chemotherapy given higher febrile neutropenia risk.

Comprehensive geriatric assessment (CGA) tools: G8 screening, VES-13.

🫘

Renal Impairment

Cisplatin is contraindicated if eGFR <60 mL/min — use carboplatin (AUC-dosed, inherently renal-adjusted).

Etoposide: reduce dose by 50% if eGFR 15–50 mL/min; use with caution if eGFR <15 mL/min.

Topotecan: reduce to 0.75 mg/m² IV if eGFR 20–39 mL/min; oral topotecan not recommended if eGFR <39 mL/min.

Immunotherapy (atezolizumab, durvalumab): no renal dose adjustment, but monitor for immune-mediated nephritis.

Patients on dialysis require specialist oncology and nephrology co-management; treatment decisions should be individualised.

Cisplatin: Contraindicated if eGFR <60 mL/min

Carboplatin: Dose by Calvert formula — inherently renal-adjusted

🫁

Hepatic Impairment

Etoposide: reduce by 50% if bilirubin 26–51 µmol/L; avoid if bilirubin >51 µmol/L. Adjust proportionally for elevated transaminases (AST/ALT >3× ULN).

Carboplatin and cisplatin: no specific hepatic dose adjustment, but use caution in severe hepatic dysfunction (Child-Pugh C).

Immunotherapy: use with extreme caution in pre-existing autoimmune hepatitis or Child-Pugh B/C cirrhosis (higher risk of immune-mediated hepatotoxicity).

Hepatic metastases are common in SCLC; differentiate treatment-related hepatotoxicity from disease progression with serial LFTs and imaging.

Etoposide: 50% dose reduction if bilirubin 26–51 µmol/L

🛡️

Immunocompromised

SCLC in immunocompromised patients (HIV, transplant recipients, immunosuppressive therapy) is rare but increasing in recognition.

HIV-positive patients with SCLC should receive standard treatment if CD4 count ≥200 cells/µL and viral load is controlled on ART. Carboplatin/etoposide is feasible with close monitoring.

Immune checkpoint inhibitors should be used cautiously in HIV-positive patients — emerging data suggest safety in well-controlled HIV, but immune reconstitution inflammatory syndrome (IRIS) is a theoretical concern.

Organ transplant recipients on immunosuppression: ICI use risks allograft rejection; requires transplant and oncology team co-management; consider immunosuppression reduction where possible.

G-CSF support is recommended for all immunocompromised patients receiving chemotherapy.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Lung cancer incidence & mortality

Aboriginal and Torres Strait Islander Australians have approximately 1.8 times the lung cancer incidence and 1.6 times the lung cancer mortality rate compared with non-Indigenous Australians. SCLC accounts for a proportionate share, with smoking prevalence in ATSI communities (approximately 37% daily smokers vs 10% non-Indigenous) being the primary driver (AIHW, 2023).

Smoking cessation

Smoking cessation remains the most impactful intervention for SCLC prevention. Culturally tailored smoking cessation programs delivered through Aboriginal Community Controlled Health Organisations (ACCHOs) show improved engagement. Pharmacotherapy (varenicline, nicotine replacement therapy) should be offered to all ATSI patients at SCLC diagnosis, regardless of stage. PBS-listed NRT is accessible through ACCHOs and Closing the Gap PBS co-payment arrangements.

Later-stage presentation

ATSI Australians are more likely to present with extensive-stage disease due to delayed diagnosis, reduced access to diagnostic services in rural/remote areas, and lower rates of incidental detection through screening. Strategies to improve early detection include community education, supporting lung cancer screening programs (the Australian Lung Cancer Screening Pilot and emerging national program), and rapid-access respiratory clinics in regional centres.

Treatment disparities

Evidence from AIHW and Cancer Council Australia indicates that ATSI patients are less likely to receive curative-intent treatment (surgery, concurrent chemoradiation) and immunotherapy, and have longer times from diagnosis to treatment initiation. Addressing this requires dedicated care coordinators, culturally safe communication, and reducing barriers to metropolitan treatment centres.

Geographic & remoteness barriers

Many ATSI Australians live in remote and very remote areas of the Northern Territory, Western Australia, and Queensland with limited access to oncology services, PET-CT, and specialist MDTs. Teleoncology services (e.g., through the Royal Darwin Hospital, Peter MacCallum regional partnerships) are critical. Treatment travel support through Patient Assisted Travel Schemes (PATS) and state/territory equivalents must be facilitated.

Cultural safety & communication

All interactions should be culturally safe, with acknowledgement of Country, use of interpreters for patients whose first language is not English, and understanding of kinship obligations and sorry business. Advance care planning should be approached sensitively, respecting community and family decision-making processes. Aboriginal Health Workers and Liaison Officers (AHWLOs) should be involved in all stages of care.

Follow-up & survivorship

Follow-up adherence may be challenging due to mobility, family obligations, and distrust of healthcare systems shaped by historical trauma. Flexible follow-up models incorporating ACCHOs, community-based care, and shared-care arrangements with local health services improve outcomes. Palliative care services should be culturally adapted and, where possible, delivered in community settings to support end-of-life care on Country.

📚 References

1. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
2. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
3. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–271. doi:10.1056/NEJM199901283400403
4. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476–484. doi:10.1056/NEJM199908123410703
5. Slotman BJ, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–672. doi:10.1056/NEJMoa071780
6. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645–654. doi:10.1016/S1470-2045(20)30068-1
7. National Health and Medical Research Council (NHMRC). Clinical Practice Guidelines for the Prevention, Diagnosis, and Management of Lung Cancer. Canberra: NHMRC; 2024.
8. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2023: AIHW Cat. No. CAN 143. Canberra: AIHW; 2023.
9. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Lung Cancer. Canberra: AIHW; 2023.
10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2024. Plymouth Meeting, PA: NCCN; 2024.
11. Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi99–vi105. doi:10.1093/annonc/mdt178
12. Cancer Council Australia. Lung Cancer Guidelines Wiki. Sydney: Cancer Council Australia; 2024. Available at: wiki.cancer.org.au
13. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009
14. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42. doi:10.1016/S0140-6736(14)61183-8
15. Royal Australian College of General Practitioners (RACGP). Guidelines for Preventive Activities in General Practice. 9th edn. Melbourne: RACGP; 2018.